Abstract
Serotonin4 (5-HT4) receptors have been shown to be involved in several peripheral and central functions, including control of the gastro-intestinal tract, modulation of memory and food intake, as well as positive regulation of the release of various neurotransmitters. Recently, we have proposed that the study of these receptors may also bring a new hope for treating depression, their agonists possibly acting as fast-acting antidepressants. This hypothesis was based on several studies showing that 5-HT4 receptors play an important role in the modulation of central 5-HT neurotransmission, both at pre- and postsynaptic levels. The possible physiological meaning of this control is discussed, together with the different research perspectives opened by its discovery.
Keywords: Depression, 5-HT neurons, 5-HT4 receptors, fast-acting antidepressants, dorsal raphe nucleus, modulation of mood
Current Drug Targets
Title: Serotonin Receptors, Type 4: A New Hope?
Volume: 10 Issue: 11
Author(s): Guillaume Lucas
Affiliation:
Keywords: Depression, 5-HT neurons, 5-HT4 receptors, fast-acting antidepressants, dorsal raphe nucleus, modulation of mood
Abstract: Serotonin4 (5-HT4) receptors have been shown to be involved in several peripheral and central functions, including control of the gastro-intestinal tract, modulation of memory and food intake, as well as positive regulation of the release of various neurotransmitters. Recently, we have proposed that the study of these receptors may also bring a new hope for treating depression, their agonists possibly acting as fast-acting antidepressants. This hypothesis was based on several studies showing that 5-HT4 receptors play an important role in the modulation of central 5-HT neurotransmission, both at pre- and postsynaptic levels. The possible physiological meaning of this control is discussed, together with the different research perspectives opened by its discovery.
Export Options
About this article
Cite this article as:
Lucas Guillaume, Serotonin Receptors, Type 4: A New Hope?, Current Drug Targets 2009; 10 (11) . https://dx.doi.org/10.2174/138945009789735200
DOI https://dx.doi.org/10.2174/138945009789735200 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inflammatory Process as a Determinant Factor for the Degeneration of Substantia Nigra Dopaminergic Neurons: Possible Relevance to the Etiology of Parkinsons Disease
Current Medicinal Chemistry - Central Nervous System Agents The Role of N-Methyl-D-Aspartate Receptor - Mediated Neurotransmission in Attention Deficit (Hyperactivity) Disorder (ADHD/ADD)
Current Psychopharmacology Adenosine A<sub>2A</sub> Receptor Antagonists as Positron Emission Tomography (PET) Tracers
Current Medicinal Chemistry Age-Related Changes in Motor Cortical Properties and Voluntary Activation of Skeletal Muscle
Current Aging Science Trafficking and Signaling of G Protein-Coupled Receptors in the Nervous System: Implications for Disease and Therapy
CNS & Neurological Disorders - Drug Targets Neural Correlates of Schizotypal Personality Disorder: A Systematic Review of Neuroimaging and EEG Studies
Current Medical Imaging Targeting the Mitochondrial Electron Transport Chain Complexes for the Induction of Apoptosis and Cancer Treatment
Current Pharmaceutical Biotechnology Is rTMS an Effective Therapeutic Strategy that Can Be Used to Treat Parkinson's Disease?
CNS & Neurological Disorders - Drug Targets Editorial (Hot Topic: Regenerative Medicine in Neurological Diseases)
Recent Patents on Regenerative Medicine Neurobiological Basis of Dyskinetic Effects Induced by Antipsychotics: the Contribution of Animal Models
Current Medicinal Chemistry Modulation of Neuro-Inflammation and Vascular Response by Oxidative Stress Following Cerebral Ischemia-Reperfusion Injury
Current Medicinal Chemistry Endothelins Role in the Control of the Acute Phase of Trypanosoma cruzi Infection
Mini-Reviews in Medicinal Chemistry Insulin-Like Growth Factor-1 and its Derivatives: Potential Pharmaceutical Application for Treating Neurological Conditions
Recent Patents on CNS Drug Discovery (Discontinued) An Agathokakological Tale of Δ<sup>9</sup>-THC: Exploration of Possible Biological Targets
Current Drug Targets Brain Structural Abnormalities at the Onset of Schizophrenia and Bipolar Disorder: A Meta-analysis of Controlled Magnetic Resonance Imaging Studies
Current Pharmaceutical Design Microglia:Neuroprotective and Neurotrophic Cells in the Central Nervous System
Current Drug Targets - Cardiovascular & Hematological Disorders Serotonin Involvement in the Basal Ganglia Pathophysiology: Could the 5-HT2C Receptor be a New Target for Therapeutic Strategies?
Current Medicinal Chemistry Does Parkinson’s Disease and Type-2 Diabetes Mellitus Present Common Pathophysiological Mechanisms and Treatments?
CNS & Neurological Disorders - Drug Targets Peripheral Chemo-Cytokine Profiles in Alzheimers and Parkinsons Diseases
Mini-Reviews in Medicinal Chemistry Endocannabinoid System in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued)